Change in Residual beta cell function in Newly diagnosed T1 diabetes children receiving lansoprazole and vitamin D supplementatio
Not Applicable
- Conditions
- Health Condition 1: E101- Type 1 diabetes mellitus with ketoacidosis
- Registration Number
- CTRI/2021/07/034989
- Lead Sponsor
- Raghunatha Reddy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly diagnosed patients with T1Diabetes
Autoantibodies positivity
Baseline c peptide 0.5 ng/ml
Children receiving lansoprazole for dyspeptic symtptoms
Exclusion Criteria
Presence of other autoimmune disease
Vitamin D deficiency <20 ng/ml
Patient on vitamin D /other multivitamin supplementation
Children with preexisting renal /hepatic disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in FCP levels from baseline to study pointTimepoint: 0,3,6 months
- Secondary Outcome Measures
Name Time Method change in: <br/ ><br>1. Mean total insulin dose <br/ ><br>2. Mean HbA1c levels <br/ ><br>3. Mean blood glucose levelsTimepoint: 0 , 3 , 6 months